Next Article in Journal
Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy
Next Article in Special Issue
The Regulatory Capacity of Bivalent Genes—A Theoretical Approach
Previous Article in Journal
Diverging Concepts and Novel Perspectives in Regenerative Medicine
Previous Article in Special Issue
Epigenetic Bases of Aberrant Glycosylation in Cancer
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(5), 1017;

Exploiting Epigenetic Alterations in Prostate Cancer

Drug Discovery, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany
Author to whom correspondence should be addressed.
Academic Editor: Nicoletta Sacchi
Received: 21 April 2017 / Revised: 4 May 2017 / Accepted: 4 May 2017 / Published: 9 May 2017
(This article belongs to the Special Issue Cancer Epigenetics)
Full-Text   |   PDF [1290 KB, uploaded 9 May 2017]   |  


Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed. View Full-Text
Keywords: androgen receptor; epigenetics; histone; prostate cancer; microRNA androgen receptor; epigenetics; histone; prostate cancer; microRNA

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Baumgart, S.J.; Haendler, B. Exploiting Epigenetic Alterations in Prostate Cancer. Int. J. Mol. Sci. 2017, 18, 1017.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top